ArticlePeerJ2025
Risk factors analysis and nomogram development for myelosuppression in diffuse large B-cell lymphoma patients undergoing first-line chemotherapy: a dual-centre retrospective cohort study.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early identification of high-risk myelosuppression subtypes in DLBCL patients undergoing R-CHOP chemotherapy.Frontiers in medicine · 2026Article
- Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The primary objective of this research was to examine the characteristics of myelosuppression following first-line chemotherapy in patients suffering from diffuse large B-cell lymphoma (DLBCL). Furthermore, the study aimed to identify and analyze the risk factors impacting myelosuppression after chemotherapy and to construct a predictive model for evaluating the risk of myelosuppression. Methods: This retrospective cohort study was conducted across two medical centers. The study included 243 patients with DLBCL treated at the Anning First People's Hospital Affiliated with Kunming University of Science and Technology from January 2022 to December 2023 as the development cohort, and 107 patients treated at the Third Affiliated Hospital of Kunming Medical University from January 2024 to May 2024 as the validation cohort. The study investigated the incidence of myelosuppression in all patients, identified independent factors influencing this condition through logistic regression analysis, and constructed and validated a nomogram. Finally, the model's performance was evaluated using both internal and external validation cohorts. Results: The research rigorously incorporated a cohort of 243 DLBCL patients, with myelosuppression observed in 93 individuals (38.27%). Multifactorial analysis revealed that the chemotherapy cycle, age, Ann Arbor stage, surgical history, and neutrophil levels were independently correlated with myelosuppression following initial chemotherapy in DLBCL patients. A nomogram was developed based on the multifactorial analysis. The receiver operating characteristic (ROC) analysis revealed myelosuppression in the nomogram of both the development set (area under the curve (AUC = 0.834, 95% CI [0.785-0.884]) and the validation set (AUC = 0.861, 95% CI [0.791-0.931])), indicating clear differentiation. Further calibration curve analysis and decision curve analysis (DCA) revealed strong calibration and clinical utility of the column-line graph model. Conclusion: Patients with DLBCL are at an increased risk and frequency of myelosuppression following first-line chemotherapy. The development of a highly accurate prediction model for myelosuppression in this patient population facilitates individualized treatment strategies. Future studies should focus on expanding the sample size and developing and validating the model in additional types of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.